title: Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
authors.forename: G
authors.initials: G
authors.lastname: Meloni
authors.forename: S
authors.initials: S
authors.lastname: Capria
authors.forename: M
authors.initials: M
authors.lastname: Vignetti
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: V
authors.initials: V
authors.lastname: Modena
mesh_terms: D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000150:complications / Q000628:therapy*; D001752:Blast Crisis / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007155:Immunologic Factors / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007155:Immunologic Factors; D016898:Interferon-alpha; D000677:Amsacrine; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D002330:Carmustine; D011241:Prednisone; D008727:Methotrexate; D015255:Idarubicin